文献速递垂体与肾上腺疾病

NR3C1基因新变异的功能表征:区分糖皮质激素抵抗与库欣综合征

Characterization of a Novel Variant in the NR3C1 Gene: Differentiating Glucocorticoid Resistance From Cushing Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本文报告一名59岁男性在减重手术前发现尿游离皮质醇升高,低剂量地塞米松抑制试验异常但ACTH和午夜唾液皮质醇正常,曾被误诊为库欣病并转诊经蝶手术,68岁时确诊为原发性全身性糖皮质激素抵抗综合征。体外功能实验显示该NR3C1新杂合错义变异(p.Phe444Val)转录活性缺失但核转位正常,提示DNA结合缺陷。

要点

  • NR3C1新杂合错义变异p.Phe444Val导致原发性全身性糖皮质激素抵抗综合征。
  • 该变异转录活性缺失(GRWT 91.5 vs GRF444V 1.0)但核转位正常,提示DNA结合缺陷。
  • 认识该罕见病的临床和实验室特征有助于早期诊断,避免不必要的诊疗操作。

核心结论

  • 本文描述了一个与原发性全身性糖皮质激素抵抗综合征相关的NR3C1基因新杂合突变,强调提高对该罕见病临床和实验室特征的认识以实现早期诊断,避免不必要的和可能危险的诊断与治疗操作。

研究设计与样本

  • 病例报告:一名59岁男性在减重手术前发现尿游离皮质醇升高(体重指数39.9 kg/m2),早发高血压控制良好,低剂量地塞米松抑制试验异常但ACTH和午夜唾液皮质醇正常,最初因疑似库欣病被转诊经蝶手术,68岁时到作者科室就诊并确立GGRS临床诊断。
  • 功能表征方法:在HEK 293T细胞中通过瞬时转染实验进行体外功能表征,评估转录活性和核转位。

主要发现

  • 该变异显示转录活性缺失(GRWT:91.5 [80.5; 101.2] vs GRF444V:1.0 [1.0; 1.0]),尽管对地塞米松的核转位有效,提示该变异存在DNA结合缺陷。
  • 上述结果结合既往报告的GGRS病例进行了讨论。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Primary generalized glucocorticoid resistance syndrome (GGRS) is a rare endocrine disease caused by loss-of-function variants of the NR3C1 gene encoding the glucocorticoid receptor (GR). OBJECTIVE: We describe a novel heterozygous missense variant (NM_000176.3, c.1330T>G, p.Phe444Val) within the DNA-binding domain. CLINICAL CASE: Elevated urinary free cortisol levels were detected in a 59-year-old male patient before bariatric surgery (body mass index 39.9 kg/m2). Early-onset hypertension was well controlled. The low-dose dexamethasone suppression test was pathologic, but ACTH and midnight salivary cortisol levels were normal. The patient was initially referred to transsphenoidal surgery for a presumed diagnosis of Cushing disease. He presented to our department at the age of 68, when the clinical diagnosis of GGRS was established. METHODS: Functional characterization of the variant was performed ex vivo through transient transfection assays in HEK 293T cells to assess transcriptional activity and nuclear translocation. RESULTS: The variant showed a lack of transcriptional activity (GRWT: 91.5 [80.5; 101.2] vs GRF444V: 1.0 [1.0; 1.0]) despite efficient nuclear translocation in response to dexamethasone, suggesting a DNA binding defect of the variant. These results are discussed in the light of previously reported GGRS cases. CONCLUSION: We have described a novel heterozygous mutation of the NR3C1 gene associated with primary GGRS. This case highlights the importance of raising awareness of clinical and laboratory features of this rare disorder, to enable early diagnosis and avoid unnecessary and potentially dangerous diagnostic and therapeutic procedures.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Laulhé M, Yacobi Bach M, Perrot J, et al. Characterization of a Novel Variant in the NR3C1 Gene: Differentiating Glucocorticoid Resistance From Cushing Syndrome. J Clin Endocrinol Metab. 2025. PMID: 39607699. doi:10.1210/clinem/dgae829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。